Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Echinococcus multilocularis | muscleblind protein 1 | 0.015 | 0.3375 | 0.3266 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0095 | 0.1819 | 1 |
Entamoeba histolytica | beta-N-acetylhexosaminidase, putative | 0.0386 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.3202 | 0.3202 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0095 | 0.1819 | 1 |
Echinococcus multilocularis | beta hexosaminidase subunit alpha | 0.0241 | 0.5926 | 0.5859 |
Giardia lamblia | Kinase, PLK | 0.0095 | 0.1819 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.3202 | 0.3202 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0 | 0.5 |
Trichomonas vaginalis | beta-hexosaminidase, putative | 0.0241 | 0.5926 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0095 | 0.1819 | 0.1819 |
Schistosoma mansoni | beta-hexosaminidase B | 0.0386 | 1 | 1 |
Trypanosoma brucei | polo-like protein kinase | 0.0095 | 0.1819 | 1 |
Echinococcus granulosus | muscleblind protein | 0.015 | 0.3375 | 0.3266 |
Trichomonas vaginalis | beta-hexosaminidase B, putative | 0.0241 | 0.5926 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0095 | 0.1819 | 0.2476 |
Loa Loa (eye worm) | hypothetical protein | 0.009 | 0.1663 | 0.1663 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0095 | 0.1819 | 0.1684 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0095 | 0.1819 | 0.1684 |
Brugia malayi | Muscleblind-like protein | 0.015 | 0.3375 | 0.3375 |
Brugia malayi | hypothetical protein | 0.0036 | 0.0162 | 0.0162 |
Entamoeba histolytica | beta-N-acetylhexosaminidase, putative | 0.0386 | 1 | 1 |
Brugia malayi | Glycosyl hydrolase family 20, catalytic domain containing protein | 0.009 | 0.1663 | 0.1663 |
Brugia malayi | serine/threonine-protein kinase plk-2 | 0.0095 | 0.1819 | 0.1819 |
Trichomonas vaginalis | beta-hexosaminidase, putative | 0.0241 | 0.5926 | 1 |
Echinococcus multilocularis | beta hexosaminidase subunit beta | 0.0386 | 1 | 1 |
Trichomonas vaginalis | beta-hexosaminidase, putative | 0.009 | 0.1663 | 0.219 |
Trichomonas vaginalis | beta-hexosaminidase, putative | 0.0241 | 0.5926 | 1 |
Echinococcus granulosus | beta hexosaminidase subunit beta | 0.0386 | 1 | 1 |
Loa Loa (eye worm) | glycosyl hydrolase family 20 | 0.0386 | 1 | 1 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0095 | 0.1819 | 0.1684 |
Echinococcus multilocularis | muscleblind protein | 0.015 | 0.3375 | 0.3266 |
Echinococcus granulosus | beta hexosaminidase subunit alpha | 0.0241 | 0.5926 | 0.5859 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0095 | 0.1819 | 1 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0095 | 0.1819 | 1 |
Entamoeba histolytica | beta-N-acetylhexosaminidase, beta subunit | 0.0386 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.009 | 0.1663 | 0.1663 |
Brugia malayi | Glycosyl hydrolase family 20, catalytic domain containing protein | 0.009 | 0.1663 | 0.1663 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.015 | 0.3375 | 0.3375 |
Loa Loa (eye worm) | hypothetical protein | 0.015 | 0.3375 | 0.3375 |
Schistosoma mansoni | kinase | 0.0048 | 0.0503 | 0.0346 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0095 | 0.1819 | 0.1684 |
Schistosoma mansoni | beta-hexosaminidase B | 0.0386 | 1 | 1 |
Entamoeba histolytica | beta-N-acetylhexosaminidase, alpha subunit | 0.0386 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.3202 | 0.3202 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0522 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 0.15 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.